{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:13:52Z","timestamp":1788509632314,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xphs.2026.104302","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:47:53Z","timestamp":1777564073000},"page":"104302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Divergent host cell protein profiles during special purification of biologics from prokaryotic versus eukaryotic systems dictate the need for tailored ELISA assay development"],"prefix":"10.1016","volume":"115","author":[{"given":"Ran","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuxia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanlei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenming","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.xphs.2026.104302_bib0001","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/bit.27808","article-title":"High-risk\" host cell proteins (HCPs): a multi-company collaborative view","volume":"118","author":"Jones","year":"2021","journal-title":"Biotechnol Bioeng"},{"issue":"6","key":"10.1016\/j.xphs.2026.104302_bib0002","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1208\/s12248-016-9948-4","article-title":"Evaluating immunogenicity risk due to host cell protein impurities in antibody-based biotherapeutics","volume":"18","author":"Jawa","year":"2016","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.xphs.2026.104302_bib0003","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00253-024-13008-6","article-title":"Recombinant therapeutic proteins degradation and overcoming strategies in CHO cells","volume":"108","author":"Geng","year":"2024","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.xphs.2026.104302_bib0004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.chroma.2016.01.047","article-title":"Investigating interactions between phospholipase B-Like 2 and antibodies during Protein A chromatography","volume":"1438","author":"Tran","year":"2016","journal-title":"J Chromatogr A"},{"issue":"8","key":"10.1016\/j.xphs.2026.104302_bib0005","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.xphs.2024.05.013","article-title":"Identification of acyl-protein thioesterase-1 as a polysorbate-degrading host cell protein in a monoclonal antibody formulation using activity-based protein profiling","volume":"113","author":"\u0160prager","year":"2024","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2026.104302_bib0006","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/bit.22982","article-title":"Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity","volume":"108","author":"Gao","year":"2011","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"10.1016\/j.xphs.2026.104302_bib0007","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/btpr.2530","article-title":"Characterization of a cathepsin D protease from CHO cell-free medium and mitigation of its impact on the stability of a recombinant therapeutic protein","volume":"34","author":"Lim","year":"2018","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.xphs.2026.104302_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbiotec.2024.02.001","article-title":"SWATH-MS as a strategy for CHO host cell protein identification and quantification supporting the characterization of mAb purification platforms","volume":"384","author":"Carvalho","year":"2024","journal-title":"J Biotechnol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104302_bib0009","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/btpr.1948","article-title":"A novel approach to monitor clearance of host cell proteins associated with monoclonal antibodies","volume":"30","author":"Aboulaich","year":"2014","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.xphs.2026.104302_bib0010","series-title":"ICH Q6B: Test Procedures and Acceptance Criteria for Biotechnological\/Biological Products \u2013 Step 5","year":"1999"},{"key":"10.1016\/j.xphs.2026.104302_bib0011","series-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use","article-title":"Development and manufacture of drug substances (chemical entities and biotechnological\/biological entities) Q11","year":"2012"},{"key":"10.1016\/j.xphs.2026.104302_bib0012","series-title":"Residual Host Cell Protein Measurement in Biopharmaceuticals by Mass Spectrometry","year":"2016"},{"issue":"2","key":"10.1016\/j.xphs.2026.104302_bib0013","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/bit.26466","article-title":"Comparison of platform host cell protein ELISA to process-specific host cell protein ELISA","volume":"115","author":"Gunawan","year":"2018","journal-title":"Biotechnol Bioeng"},{"issue":"12","key":"10.1016\/j.xphs.2026.104302_bib0014","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/bit.25327","article-title":"Host cell protein testing by ELISAs and the use of orthogonal methods","volume":"111","author":"Zhu-Shimoni","year":"2014","journal-title":"Biotechnol Bioeng"},{"issue":"10","key":"10.1016\/j.xphs.2026.104302_bib0015","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/bit.25615","article-title":"More similar than different: host cell protein production using three null CHO cell lines","volume":"112","author":"Yuk","year":"2015","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"10.1016\/j.xphs.2026.104302_bib0016","doi-asserted-by":"crossref","first-page":"2375798","DOI":"10.1080\/19420862.2024.2375798","article-title":"Illuminating a biologics development challenge: systematic characterization of CHO cell-derived hydrolases identified in monoclonal antibody formulations","volume":"16","author":"Maier","year":"2024","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.xphs.2026.104302_bib0017","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/btpr.1534","article-title":"Analysis of dynamic changes in the proteome of a Bcl-XL overexpressing Chinese hamster ovary cell culture during exponential and stationary phases","volume":"28","author":"Carlage","year":"2012","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.xphs.2026.104302_bib0018","doi-asserted-by":"crossref","first-page":"114069","DOI":"10.1016\/j.jpba.2021.114069","article-title":"Toward unbiased identification and comparative quantification of host cell protein impurities by automated iterative LC-MS\/MS (HCP-AIMS) for therapeutic protein development","volume":"200","author":"Huang","year":"2021","journal-title":"J Pharm Biomed Anal"},{"issue":"16","key":"10.1016\/j.xphs.2026.104302_bib0019","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.4155\/bio-2021-0123","article-title":"Biopharmaceutical quality control with mass spectrometry","volume":"13","author":"Liu","year":"2021","journal-title":"Bioanalysis"},{"issue":"5","key":"10.1016\/j.xphs.2026.104302_bib0020","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/bit.25158","article-title":"Identification and characterization of host cell protein product-associated impurities in monoclonal antibody bioprocessing","volume":"111","author":"Levy","year":"2014","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.xphs.2026.104302_bib0021","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-0716-1450-1_9","article-title":"Purification of therapeutic antibodies by protein A affinity chromatography","volume":"2313","author":"Rathore","year":"2022","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.xphs.2026.104302_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123989","article-title":"Rapid purification of mAb using protein a membranes yielding high HCP clearance","volume":"1232","author":"Gehrmann","year":"2024","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.xphs.2026.104302_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114537","article-title":"l-asparaginase and HCP quantification by SWATH LC-MS\/MS for new and improved purification step in Erwinia chrysanthemil-asparaginase manufacture","volume":"209","author":"Modi","year":"2022","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2026.104302_bib0024","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jpba.2019.06.038","article-title":"Host cell protein quantification of an optimized purification method by mass spectrometry","volume":"174","author":"Reiter","year":"2019","journal-title":"J Pharm Biomed Anal"},{"issue":"15","key":"10.1016\/j.xphs.2026.104302_bib0025","doi-asserted-by":"crossref","first-page":"9716","DOI":"10.1021\/acs.analchem.9b01259","article-title":"Evaluation of peptide fractionation and native digestion as two novel sample preparation workflows to improve HCP characterization by LC-MS\/MS","volume":"91","author":"Kufer","year":"2019","journal-title":"Anal Chem"},{"key":"10.1016\/j.xphs.2026.104302_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2025.1579098","article-title":"A comparison of SWATH-MS methods for measurement of residual host cell proteins in adeno-associated virus preparations","volume":"13","author":"Leibiger","year":"2025","journal-title":"Front Bioeng Biotechnol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:34:31Z","timestamp":1788507271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926001516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0022354926001516"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104302","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Divergent host cell protein profiles during special purification of biologics from prokaryotic versus eukaryotic systems dictate the need for tailored ELISA assay development","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104302"}}